China's Biopharma Sector Expected to Receive More Government Support -- Market Talk

Dow Jones03-18 11:12

0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the Hang Seng Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and Ali Health.(jason.chau@wsj.com)

(END) Dow Jones Newswires

March 17, 2026 23:12 ET (03:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620858872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620858872","market":"hk","top_or_hot":-1,"title":"China's Biopharma Sector Expected to Receive More Government Support -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and <a href=\"https://laohu8.com/S/00241\">Ali Health</a>.(jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2026 23:12 ET (03:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Biopharma Sector Expected to Receive More Government Support -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Biopharma Sector Expected to Receive More Government Support -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-18 11:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and <a href=\"https://laohu8.com/S/00241\">Ali Health</a>.(jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 17, 2026 23:12 ET (03:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2264538146.SGD","symbol_name":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620858872","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620858872","pubTimestamp":1773803520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the Hang Seng Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and Ali Health.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK1142":"互联网与直销零售","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","SG9999014484.SGD":"Nikko AM ASEAN Equity Fund A SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1576":"医药外包概念","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU2152927971.USD":"NORDEA 1 ASIAN STARS EQUITY \"BP\" (USD) ACC","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","BK6523":"ESG概念","02269":"药明生物","03692":"翰森制药","BK1610":"ETF&股票定投概念","SG9999002679.SGD":"LionGlobal Singapore Balanced SGD","LU0572940350.SGD":"Janus Henderson Horizon Asian Dividend Income A3 SGD","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK1615":"港股-互联网","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","SGXZ27511609.SGD":"NIKKO AM SINGAPORE DIVIDEND EQUITY \"SGD\" (SGD) ACC","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD","SG9999013486.USD":"LIONGLOBAL SINGAPORE DIVIDEND EQUITY (USD) INC A","BK1515":"抗疫概念","01801":"信达生物","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0210637038.USD":"HSBC GIF THAI EQUITY \"AD\" INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","BK0216":"研究试验","LU0588545904.SGD":"Eastspring Investments - Asian Equity Income ASDM SGD","LU0261945553.USD":"FIDELITY ASEAN \"A\" ACC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999014492.USD":"NIKKO AM ASEAN EQUITY \"A\" (USD) ACC","00241":"阿里健康","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0051755006.USD":"摩根大通中国A (dist)","BK1502":"双十一","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD"},"translate_title":"中国生物制药行业有望获得更多政府支持——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9,"02269":0.9,"03692":0.9,"01801":0.9,"00241":0.9},"content_text":"0312 GMT - China's biopharma sector is likely to receive increased government support as a designated 'emerging pillar industry,' UOB Kay Hian analyst Carol Dou says in a note. However, she notes that the recent weak performance of the Hang Seng Healthcare Index has been driven by a new U.S. investigation into China's biotech sector and rising geopolitical tensions in the Middle East, which have triggered risk aversion. UOB KH maintains an overweight rating on the sector but flags rising geopolitical risks that could disrupt supply chains and increase market volatility. The brokerage still favors drug innovators with robust pipelines and strong earnings growth potential, as well as internet healthcare players with advanced AI algorithms. Its top sector picks are Innovent, Hansoh Pharma, WuXi AppTec, WuXi Bio and Ali Health.(jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 23:12 ET (03:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620858872","isCrawlerRequest":true}